8-fluoro-5-hydroxy-4-methyl-3-(4-pyrazol-1-ylbenzyl)-1H-quinolin-2-one | 1071496-54-2

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 8-fluoro-5-hydroxy-4-methyl-3-(4-pyrazol-1-ylbenzyl)-1H-quinolin-2-one
• 英文别名: 8-fluoro-5-hydroxy-4-methyl-3-[(4-pyrazol-1-ylphenyl)methyl]-1H-quinolin-2-one
• CAS: 1071496-54-2
• 化学式: C₂₀H₁₆FN₃O₂
• 分子量: 349.364
• InChiKey: IJOHQJKQEZQFLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  67.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-fluoro-5-hydroxy-4-methyl-3-(4-pyrazol-1-ylbenzyl)-1H-quinolin-2-one 在 三氯氧磷 、 水 作用下， 反应 1.0h， 生成 phosphoric acid mono[8-fluoro-4-methyl-2-oxo-3-(4-pyrazol-1-ylbenzyl)-1,2-dihydroquinolin-5-yl]ester
  参考文献：
  名称：

  WO2008/122784

  摘要：

  公开号：

文献信息

• [EN] QUINOLIN-2-ONE COMPOUNDS<br/>[FR] COMPOSÉS DE QUINOLIN-2-ONE
  申请人：ARGENTA ORAL THERAPEUTICS LTD

  公开号：WO2010040989A1

  公开（公告）日：2010-04-15

  A compound of structural formula [1]: in which: A represents a direct bond, an optionally substituted alkylene or alkenylene group, or a group of formula Z-(optionally substituted)alkylene; B represents a direct bond, an optionally substituted alkylene or alkenylene group, or a group of formula Z-(optionally substituted)alkylene or (optionally substituted)alkylene-Z; Z represents an oxygen atom, an NH or N-alkyl group, a group of formula S(O)n, in which n = 0 to 2, or a group of formula -O-SO2-; X represents a carboxylic acid, tetrazole, 3-hydroxyisoxazole, hydroxamic acid, phosphinate, phosphonate, phosphonamide, sulfonic acid or a group of formula C(=O)NHSO2W or SO2NHC(=O)W; W represents an optionally substituted aryl or heteroaryl group or an optionally substituted alkyl group; Y represents an optionally substituted aryl or heteroaryl group, or an optionally substituted aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl, aryl-fused-cycloalkyl or cycloalkyl group; Ra, Rb and Rc independently represent hydrogen, acyl, alkoxy, alkylsulphinyl, alkylsulphonyl, alkylthio, -NH2, aminoalkyl, hydroxyalkyl, arylalkyl, cyano, dialkylamino, halo, haloalkoxy, haloalkyl, alkyl, alkenyl, -OH, -CHO, -NO2, aryl (optionally substituted with alkoxy, haloalkoxy, halogen, alkyl or haloalkyl), heteroaryl (optionally substituted with alkoxy, haloalkoxy, halogen, alkyl or haloalkyl), heterocycloalkyl, aminoacyl, aminosulphonyl, acylamino, sulphonylamino, heteroarylalkyl, cyclic amine, aryloxy, heteroaryloxy, arylalkyloxy or heteroarylalkyloxy;

  结构式[1]的化合物：其中：A代表直链键，可选择取代的烷基或烯基基团，或者公式Z-(可选择取代)烷基；B代表直链键，可选择取代的烷基或烯基基团，或者公式Z-(可选择取代)烷基或(可选择取代)烷基-Z；Z代表氧原子，NH或N-烷基基团，公式S(O)n中的基团，其中n = 0至2，或者公式-O-SO2-的基团；X代表羧酸，四唑，3-羟基异噁唑，羟肟酸，膦酸酯，膦酸酰，膦酰胺，磺酸或者公式C(=O)NHSO2W或SO2NHC(=O)W的基团；W代表可选择取代的芳基或杂环芳基，或者可选择取代的烷基基团；Y代表可选择取代的芳基或杂环芳基，或者可选择取代的芳基-融合-杂环烷基，杂环芳基-融合-环烷基，杂环芳基-融合-杂环烷基，芳基-融合-环烷基或环烷基基团；Ra、Rb和Rc独立地代表氢、酰基、烷氧基、烷基磺酰基、烷基磺基、烷基硫基、-NH2、氨基烷基、羟基烷基、芳基烷基、氰基、二烷基氨基、卤素、卤代烷氧基、卤代烷基、烷基、烯基、-OH、-CHO、-NO2、芳基（可选择取代烷氧基、卤代烷氧基、卤素、烷基或卤代烷基）、杂环芳基（可选择取代烷氧基、卤代烷氧基、卤素、烷基或卤代烷基）、杂环烷基、氨基酰、氨基磺酰、酰胺基、磺酰胺基、杂环芳基烷基、环胺基、芳氧基、杂环氧基、芳基烷氧基或杂环芳基烷氧基；
• Quinolines and Their Therapeutic Use
  申请人：Montana John Gary

  公开号：US20100144787A1

  公开（公告）日：2010-06-10

  Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R 1 is halogen or cyano; R 2 is hydrogen or methyl; R 3 and R 4 are independently —OR 6 , C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; R 5 is hydrogen or halogen; R 6 is C 1 C 6 alkyl or C 3 -C 6 cycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is —CH 2 —, —S—, or —O—; one of Y and Y 1 is hydrogen and the other is OR 6 , —C(═O)R 7 , NR 8 SO 2 R 6 or a heterocyclic group selected from those referred to in the specification; and R 6 , R 7 and R 8 are as defined in the specification.

  式(I)的化合物是CRTH2配体，在治疗哮喘和COPD等疾病中有用，其中：R1为卤素或氰基；R2为氢或甲基；R3和R4分别为—OR6、C1-C6烷基或C3-C6环烷基，后两个基团可选地被一个或多个卤素原子取代；R5为氢或卤素；R6为C1-C6烷基或C3-C6环烷基，其中任意一个可选地被一个或多个卤素原子取代；X为—CH2—、—S—或—O—；Y和Y1中的一个为氢，另一个为OR6、—C(═O)R7、NR8SO2R6或从规范中选择的杂环基团；R6、R7和R8如规范中所定义。
• Quinolines and their therapeutic use
  申请人：Pulmagen Therapeutics (Asthma) Limited

  公开号：US08173812B2

  公开（公告）日：2012-05-08

  Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R1 is halogen or cyano; R2 is hydrogen or methyl; R3 and R4 are independently —OR6, C1-C6alkyl or C3-C6cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; R5 is hydrogen or halogen; R6 is C1-C6 alkyl or C3-C6 cycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is —CH2—, —S—, or —O—; one of Y and Y1 is hydrogen and the other is OR6, —C(═O)R7, NR8SO2R6 or a heterocyclic group selected from those referred to in the specification; and R6, R7 and R8 are as defined in the specification.

  式(I)的化合物是CRTH2配体，在治疗哮喘和COPD等疾病中有用，其中：R1是卤素或氰基；R2是氢或甲基；R3和R4独立地是—OR6、C1-C6烷基或C3-C6环烷基，后两种基团可选择地被一个或多个卤素原子取代；R5是氢或卤素；R6是C1-C6烷基或C3-C6环烷基，其中任意一个都可以选择地被一个或多个卤素原子取代；X是—CH2—、—S—或—O—；Y和Y1中的一个是氢，另一个是OR6、—C(═O)R7、NR8SO2R6或在说明书中提到的选定的杂环基团；R6、R7和R8如说明书所定义。
• QUINOLINES AND THEIR THERAPEUTIC USE
  申请人：Argenta Oral Therapeutics Limited

  公开号：EP2139881A1

  公开（公告）日：2010-01-06
• US8173812B2
  申请人：——

  公开号：US8173812B2

  公开（公告）日：2012-05-08